Evidence map›Paper›PMID 31495827›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

A Novel Chinese Medicine, Xinfeng Capsule, Modulates Proinflammatory Cytokines via Regulating the Toll-Like Receptor 4 (TLR4)/Mitogen-Activated Protein Kinase (MAPK)/Nuclear Kappa B (NF-κB) Signaling Pathway in an Adjuvant Arthritis Rat Model.

Yun-Xiang Cao, Dan Huang, Jian Liu, Rui-Kai Zong, Lei Wan, Chuan-Bing Huang, Wan-Dong Zhang, Yuan Wang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in immunology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yun-Xiang CaoDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Dan HuangDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Jian LiuDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Rui-Kai ZongDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Lei WanDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Chuan-Bing HuangDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Wan-Dong ZhangDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Yuan WangDepartment of Rheumatology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine (TCM), Hefei, Anhui, China (mainland).
Anhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Rheumatoid arthritis (RA) is a chronic autoimmune disease targeting joints. This research aimed to explore the effects of Xinfeng capsules (XFC) on cardiac injury in adjuvant arthritis (AA) model rats and assessed the associated mechanism. MATERIAL AND METHODS An adjuvant arthritis (AA) rat model was established by intracutaneously injection with Freund's complete adjuvant (FCA). Model rats were divided into 4 groups: an AA model group, an astragalus polysaccharides (APS) group, a methotrexate (MTX) group, and an XFC and triptolide (TPT) group. Hematoxylin-eosin (HE) staining was used to observe histopathologic changes. TUNEL assay was utilized to evaluate the apoptosis of cardiomyocytes. ELISA was utilized to evaluate levels of tumor necrosis factor alpha (TNF-alpha), interleukin 17 (IL-17), and interleukin 6 (IL-6) in myocardial tissues. Quantitative RT-PCR (qRT-PCR) was used to detect microRNA-21 (miRNA21) levels. Mitogen-activated protein kinase (MAPK)/p38, Toll-like receptor 4 (TLR4), and nuclear kappa B (NF-kappaB)/p65 levels were evaluated using Western blot. RESULTS XFC significantly improved proinflammatory response compared to the AA model group (p<0.05). XFC treatment significantly decreased the number of cells staining TUNEL-positive compared with the model group (p<0.05). XFC treatment significantly reduced TNF-alpha, IL-17, and IL-6 levels in myocardial tissues compared to the model group (p<0.05). Levels of miRNA21 were significantly lower in the XFC group compared to the AA model group (p<0.05). TLR4, MAPK/p38, and NF-kappaB/p65 expression levels were significantly lower in the XFC group than in the model group (p<0.05). CONCLUSIONS Xinfeng capsule, a traditional Chinese medicine preparation, protects against cardiac injury in AA rats by modulating proinflammatory cytokines expression via the TLR4/MAPK/NF-kappaB signaling pathway.

Indexed as

AnimalsApoptosisArthritis, ExperimentalCapsulesCytokinesDisease Models, AnimalDrugs, Chinese HerbalGene Expression RegulationInflammationInflammation MediatorsMicroRNAsMitogen-Activated Protein KinasesMyocardiumNF-kappa Bp38 Mitogen-Activated Protein KinasesPhosphorylationCapsulesCytokinesDrugs, Chinese HerbalInflammation MediatorsMicroRNAsmirn21 microRNA, ratMitogen-Activated Protein KinasesNF-kappa Bp38 Mitogen-Activated Protein KinasesToll-Like Receptor 4xinfeng

Identifiers

PMID31495827
PMCPMC6752099
OpenAlexW2972316165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.